At Single Point of Contact, we’ve seen a consistent pattern across biotech environments: the breach rarely begins when the alarm is triggered, it begins months earlier, quietly, patiently, and often unnoticed.
And that’s the part most leadership teams underestimate.
Biotech firms operate under a dangerous assumption: that if systems are functioning and users are productive, the environment is secure. But in reality, attackers are not trying to break your systems, they’re trying to live inside them without being noticed.
So let’s address the question directly.
How long do biotech breaches typically go undetected?
Industry-wide, the average dwell time, the period between initial compromise and detection often ranges from:
- 150 to 250+ days in complex environments
- Longer in decentralized or research-heavy infrastructures
- Indefinite in cases where monitoring is fragmented or reactive
That’s not a technical issue. That’s a business risk.
Because during those “silent months,” attackers are not idle.
They are mapping your environment. They are identifying key personnel. They are locating intellectual property. And most importantly they are waiting for the right moment to extract value.
Why Biotech Is a Prime Target
Unlike other industries, biotech doesn’t just store data, it creates it.
And that creates a different type of threat:
- Pre-clinical research can be exfiltrated before patent protection
- Trial data can be manipulated or stolen mid-cycle
- Partnership negotiations can be compromised before public disclosure
This is not hypothetical. It’s strategic. Attackers understand that the true value of biotech data is time-sensitive. The earlier they access it, the more leverage they gain.
The Real Cost of Delayed Detection
Most executive teams think in terms of breach response: recovery, insurance, and remediation. But the real damage happens before the breach is discovered.
Consider what 200 days of undetected access can mean:
- Compromised R&D timelines
Sensitive research may already be in external hands before your team even suspects an issue. - Loss of competitive advantage
Years of innovation can be quietly replicated or sold. - Delayed funding or failed partnerships
Due diligence processes uncover inconsistencies or risks you didn’t know existed. - Regulatory exposure
Undetected access may violate HIPAA, GDPR, or FDA data integrity requirements long before disclosure. - Internal trust erosion
Leadership begins to question not just security, but operational visibility.
Why Detection Takes So Long
This is where most organizations need to be brutally honest.
Breaches don’t go undetected because attackers are unstoppable.
They go undetected because environments are not designed to see them.
Common gaps include:
- Overreliance on endpoint tools without centralized visibility
- Lack of 24/7 monitoring across hybrid environments
- Alert fatigue causing real threats to be ignored
- Disconnected systems across labs, cloud platforms, and vendors
- Assumption that compliance equals security
The reality? Most internal IT teams are not structured to detect subtle, long-term threats. They are built to maintain uptime not hunt adversaries.
A Strategic Shift Leaders Must Make
This is not a call for more tools. It’s a call for a different mindset.
Detection must be treated as a continuous business function, not a reactive IT task.
That means:
- Understanding that time-to-detect = risk exposure window
- Accepting that visibility gaps are inevitable without dedicated monitoring
- Prioritizing early signal detection over post-incident response
Because once a breach is discovered, the question is no longer “what happened?”
It’s:
“How long have they been here?”
And in biotech, that question can define the future of your pipeline.
Closing Thought
If your organization does not have continuous visibility across endpoints, users, and data movement, then you are not measuring detection time you are extending it.
At Single Point of Contact, we work with biotech firms that recognize this shift. Not as a vendor decision, but as a business necessity.
Because the goal is not just to respond to threats.
It’s to find them before they become outcomes.
If your current environment cannot answer the question, “Would we know within hours not months?” then the exposure isn’t theoretical.
It’s already in motion.
About Single Point of Contact
Single Point of Contact is an experienced MSP in the biotech industry and is a valuable partner, providing specialized knowledge in implementing robust backup strategies and ensuring network security and stability. With deep understanding of regulatory requirements such as HIPAA and FDA’s 21 CFR Part 11, Single Point of Contact safeguards sensitive research data, clinical trial information, and intellectual property. They offer tailored solutions, including automated backups, real-time monitoring, and disaster recovery plans, minimizing downtime and data loss. By managing security protocols, they protect against cyber threats, allowing biotech companies to focus on innovation while ensuring compliance and uninterrupted operations. This expertise enhances productivity and reduces risk. Contact us today to discover more about how we can help your biotech firm with DR, backup and security.
